Literature DB >> 35913632

Primary mucosal melanoma of the larynx: systematic review of the literature and qualitative synthesis.

Ignacio Javier Fernandez1, Federico Spagnolo2, Leonardo Roncadi3, Giulia Molinari1, Daniele Marchioni3, Livio Presutti1, Daniela Lucidi3.   

Abstract

PURPOSE: Primary mucosal melanoma of the larynx (PLM) is a rare entity among head and neck cancers. Due to its rarity, clear protocols of management are not available. A deeper knowledge of the clinical and biological behaviour of PLM is strongly needed.
METHODS: According to PRISMA process, we searched through electronic databases case reports, case series and review articles providing relevant clinical data. The survival analysis was performed with Kaplan-Meier survival curves, using disease free survival (DFS) and overall survival (OS) as endpoints.
RESULTS: 1074 articles were initially screened, of which 37 studies describing 44 PLM cases were selected and included in the analysis. Mean age was 59.7 years with a mean follow-up time of 25.4 months. The most common symptom at presentation was hoarseness (52%), while the most involved laryngeal subsite was supraglottic region (62%). Most patients presented with an advanced stage. Tumour (T) and node (N) status at presentation did not influence OS nor DFS, whereas distant metastases (M) status resulted significantly associated with the reduction of OS and DFS time (Mantel-Cox: p < 0.0001 and p = 0.001, respectively). The laryngeal subsite and the type of surgery performed did not significantly impact on OS and DFS.
CONCLUSIONS: Treatment for PLM remains debated. Surgery with safe margins is recommended due to the high rates of local recurrence. Systemic therapy is advised for metastatic disease. However, the prognosis remains poor even after radical resection or targeted therapy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Larynx; Molecular biology; Mucosal melanoma; Survival; Systematic review

Year:  2022        PMID: 35913632     DOI: 10.1007/s00405-022-07565-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   3.236


  29 in total

Review 1.  Immunohistochemical characteristics of melanoma.

Authors:  Steven J Ohsie; G Peter Sarantopoulos; Alistair J Cochran; Scott W Binder
Journal:  J Cutan Pathol       Date:  2008-05       Impact factor: 1.587

2.  Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis.

Authors:  A C ALLEN; S SPITZ
Journal:  Cancer       Date:  1953-01       Impact factor: 6.860

Review 3.  Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas.

Authors:  Stacey E Mills
Journal:  Mod Pathol       Date:  2002-03       Impact factor: 7.842

4.  Incidence of noncutaneous melanomas in the U.S.

Authors:  Colleen C McLaughlin; Xiao-Cheng Wu; Ahmedin Jemal; Howard J Martin; Lisa M Roche; Vivien W Chen
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

5.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Mucosal Melanomas.

Authors:  Michelle D Williams
Journal:  Head Neck Pathol       Date:  2017-02-28

6.  Mucosal melanoma of the head and neck: 32-year experience in a tertiary referral hospital.

Authors:  Richie Chiu-Lung Chan; Jimmy Yu Wai Chan; William Ignace Wei
Journal:  Laryngoscope       Date:  2012-11-14       Impact factor: 3.325

7.  Primary malignant melanoma of the larynx.

Authors:  H H Amin; G J Petruzzelli; A N Husain; B J Nickoloff
Journal:  Arch Pathol Lab Med       Date:  2001-02       Impact factor: 5.534

Review 8.  Primary mucosal melanomas: a comprehensive review.

Authors:  Marija Mihajlovic; Slobodan Vlajkovic; Predrag Jovanovic; Vladisav Stefanovic
Journal:  Int J Clin Exp Pathol       Date:  2012-10-01

9.  Laryngeal mucosal malignant melanoma. A clinicopathologic, immunohistochemical, and ultrastructural study of four patients and a review of the literature.

Authors:  B M Wenig
Journal:  Cancer       Date:  1995-04-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.